Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-01-30
2007-01-30
Huff, Sheela J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S350000
Reexamination Certificate
active
10651723
ABSTRACT:
The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising:a) selecting at least one peptide that modulates the activity of a protein of interest; andb) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide.Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display,E. colidisplay, ribosome display, RNA-peptide screening, or chemical-peptide screening.
REFERENCES:
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5216131 (1993-06-01), Lasky et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5284656 (1994-02-01), Platz et al.
patent: 5336603 (1994-08-01), Capon et al.
patent: 5338665 (1994-08-01), Schatz et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5432018 (1995-07-01), Dower et al.
patent: 5455165 (1995-10-01), Capon et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5498530 (1996-03-01), Schatz et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5565335 (1996-10-01), Capon et al.
patent: 5608035 (1997-03-01), Yanofsky et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5726290 (1998-03-01), Bodary et al.
patent: 5733731 (1998-03-01), Schatz et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5767234 (1998-06-01), Yanofsky et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5786331 (1998-07-01), Barrett et al.
patent: 5840844 (1998-11-01), Lasky et al.
patent: 5869451 (1999-02-01), Dower et al.
patent: 5869452 (1999-02-01), Ng et al.
patent: 5877151 (1999-03-01), Pereira
patent: 5880096 (1999-03-01), Barrett et al.
patent: 5922545 (1999-07-01), Mattheakis et al.
patent: 5932546 (1999-08-01), Barrett et al.
patent: 5985599 (1999-11-01), McKenzie et al.
patent: 6117655 (2000-09-01), Capon et al.
patent: 0 173 494 (1986-03-01), None
patent: 0 325 224 (1989-07-01), None
patent: 0 526 452 (1993-02-01), None
patent: 0 585 287 (1994-03-01), None
patent: 0 911 393 (1999-04-01), None
patent: 0 714 912 (1999-05-01), None
patent: 1 029 870 (2000-08-01), None
patent: WO 94/07921 (1994-04-01), None
patent: WO 95/09917 (1995-04-01), None
patent: WO 95/14714 (1995-06-01), None
patent: WO 96/05309 (1996-02-01), None
patent: WO 96/11214 (1996-04-01), None
patent: WO 96/11953 (1996-04-01), None
patent: WO 96/17942 (1996-06-01), None
patent: WO 96/18412 (1996-06-01), None
patent: WO 96/23899 (1996-08-01), None
patent: WO 96/30057 (1996-10-01), None
patent: WO 96/40772 (1996-12-01), None
patent: WO 96/40987 (1996-12-01), None
patent: WO 97/00270 (1997-01-01), None
patent: WO 97/08203 (1997-03-01), None
patent: WO 97/08553 (1997-03-01), None
patent: WO 97/23614 (1997-07-01), None
patent: WO 97/28828 (1997-08-01), None
patent: WO 97/31019 (1997-08-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 97/35969 (1997-10-01), None
patent: WO 97/40070 (1997-10-01), None
patent: WO 97/44453 (1997-11-01), None
patent: WO 98/09985 (1998-03-01), None
patent: WO 98/10795 (1998-03-01), None
patent: WO 98/15833 (1998-04-01), None
patent: WO 98/24477 (1998-06-01), None
patent: WO 98/28427 (1998-07-01), None
patent: WO 98/31820 (1998-07-01), None
patent: WO 98/33812 (1998-08-01), None
patent: WO 98/46257 (1998-10-01), None
patent: WO 98/53842 (1998-12-01), None
patent: WO 98/55620 (1998-12-01), None
patent: WO 99/05302 (1999-02-01), None
patent: WO 99/14244 (1999-03-01), None
patent: WO 99/17789 (1999-04-01), None
patent: WO 99/18243 (1999-04-01), None
patent: WO 99/18781 (1999-04-01), None
patent: WO 99/24462 (1999-05-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/24782 (2000-05-01), None
patent: WO 01/02440 (2001-01-01), None
Adey et al. (1996), ‘Identification of calmodulin-binding peptide consensus sequences from a phage-displayed random peptide library’,Gene169:133-134.
Adey et al. (1997), ‘Isolation of peptides from phage-displayed random peptide libraries that interact with the talin-binding domain of vinculin’,Biochem. J. 326:523-528.
Ahern et al. (1990), ‘Special Report: The Peptide-Oligonucleotide Partnership’,The Scientist4 (19):24-25.
Akeson et al. (1996), ‘AF12198, a Novel Low Molecular Weight Antagonist, Selectively Binds the Human Type I Interleukin (IL)-1 Receptor and Blocks in vivo Responses to IL-1’,J. Biol. Chem. 271:30517-30523.
Ball et al. (1997), Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1,,Current Biology7:71-80.
Becker et al. (1989), “Expression of a Hybrid Immunoglobulin- T cell Receptor Protein in Transgenic Mice,”Cell58: 911-921.
Bernard et al. (1980), “Nucleotide sequence of immunoglobulin heavy chain joining segments between translocated VHand μ constant region genes,”Proc. Natl. Sci. USA77(6): 3630-3634.
Bhatnagar et al. (1996), ‘Structure-Activity Relationships of Novel Hematoregulatory Peptides’,J. Med. Chem. 39:3814-3819.
Böttger et al. (1996), ‘Identification of novel mdm2 binding peptides by phage display’,Oncogene13:2141-2147.
Böttger et al. (1997), ‘Molecular Characterization of the hdm2-p53 Interaction’,J. Mol. Biol. 269:744-756..
Boulianne et al. (1984), “Production of functional chimaeric Mousem/human antibody,”Nature312: 643-646.
Brocks et al. (1997), “A TNF receptor antagonistic scFv, which is not secreted in mammalian cells, is expressed as a soluble mono- and bivalent scFv derivative in insect cells,”Immunotechnology3(3):173-184.
Burstein et al. (1988), ‘Thymic Humoral Factor γ2: Purification and Amino Acid Sequence of an Immunoregulatory Peptide from Calf Thymus’,Biochemistry27:4066-4071.
Capon et al. (1989), ‘Designing CD4 Immunoadhesins for AIDS Therapy’,Nature337:525-531.
Chamow et al. (1996), “Immunoadhesins: principles and applications,”Tibtech14:52-60.
Chirinos-Rojas et al. (1998), ‘A Peptidomimetic Antagonist of TNF-α-Mediated Cytotoxicity Identified from a Phage-Displayed Random Peptide Library’,Journal of Immunology161:5621-5626.
Cooper et al. (1987), ‘Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients’,PNAS84:8628-8632.
Cortese et al. (1996), ‘Selection of biologically active peptides by phage display of random peptide libraries’,Current Opinion in Biotechnology 7:616-621.
Couet et al. (1997), ‘Identification of Peptide and Protein Ligands for the Caveolin-scaffolding Domain’,The Journal of Biological Chemistry272 (10):6525-6533.
Couet et al. (1997), ‘Interaction of a Receptor Tyrosine Kinase, EGF-R, with Caveloins’,The Journal of Biological Chemistryvol. 272 (48):30429-30438.
Cuthbertson et al. (1997), ‘Design of Low Molecular Weight Hematoregulatory Agents from the Structure-Activity Relationship of a Dimeric Pentapeptide’,J. Med. Chem40:2876-2882.
Cwirla et al. (1997), ‘Peptide Agonist of the Thrombopoietin Receptors’,Science276:1696-1699.
Dedman et al. (1993), ‘Selection of Targeted Biological Modifiers from a Bacteriophage Library of Random Peptides’,The Journal of Biological Chemistry268 (31):23025-23030.
Devlin et al. (1990), ‘Random Peptide Libraries: A Source of Specific Protein Binding Molecules’,Science249:404-406.
Duncan et al. (1988), ‘Localization of the binding site for the human high-affinity Fc receptor on IgG’,Nature332:563-564.
Dyson et al. (1995), ‘Selection of peptide inhibitors of interactions involved in complex protein assemblies: Association of the core and surface anti
Amgen Inc.
Gaul Timothy J.
Huff Sheela J.
LandOfFree
Modified peptides as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified peptides as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified peptides as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3748031